A Retrospective Study of Amitriptyline in Youth with Autism Spectrum Disorders

We performed a retrospective chart review of 50 youths with Autism Spectrum Disorder (ASD), prescribed amitriptyline (AMI) for hyperactivity and impulsivity. Data was systematically extracted from 50 outpatient clinic charts, including AMI treatment duration, dose, trough levels and adverse events....

Full description

Saved in:
Bibliographic Details
Published in:Journal of autism and developmental disorders 2013-05, Vol.43 (5), p.1017-1027
Main Authors: Bhatti, Irfan, Thome, Andrew, Smith, Patricia Oxler, Cook-Wiens, Galen, Yeh, Hung Wen, Gaffney, Gary R., Hellings, Jessica A.
Format: Article
Language:English
Subjects:
Adolescent
Adolescents
Adrenergic Uptake Inhibitors - therapeutic use
Aggression
Amitriptylene
Amitriptyline
Amitriptyline - therapeutic use
Anxiety Disorders
Atomoxetine Hydrochloride
Autism
Autism Spectrum Disorders
Autistic spectrum disorders
Behavior Problems
Behavioral Science and Psychology
Biological and medical sciences
Child
Child and School Psychology
Child clinical studies
Child Development Disorders, Pervasive - drug therapy
Child, Preschool
Complications and side effects
Developmental disorders
Dosage
Dosage and administration
Drug Therapy
Female
Humans
Hyperactivity
Impulsivity
Infantile autism
Male
Medical sciences
Neuropharmacology
Neurosciences
Original Paper
Outcomes of Treatment
Pediatrics
Pervasive Developmental Disorders
Pharmacology. Drug treatments
Prognosis
Propylamines - therapeutic use
Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer
Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease)
Psychology
Psychology. Psychoanalysis. Psychiatry
Psychopathology. Psychiatry
Psychopharmacology
Public Health
Retreatment
Retrospective Studies
Symptoms (Individual Disorders)
Treatment Outcome
Young people
Youth
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c629t-2a3f6b97360a02d8ac611e3c1ed7c47ed237760ceb61f71ead9db31ad19e8aa53
cites cdi_FETCH-LOGICAL-c629t-2a3f6b97360a02d8ac611e3c1ed7c47ed237760ceb61f71ead9db31ad19e8aa53
container_end_page 1027
container_issue 5
container_start_page 1017
container_title Journal of autism and developmental disorders
container_volume 43
creator Bhatti, Irfan
Thome, Andrew
Smith, Patricia Oxler
Cook-Wiens, Galen
Yeh, Hung Wen
Gaffney, Gary R.
Hellings, Jessica A.
description We performed a retrospective chart review of 50 youths with Autism Spectrum Disorder (ASD), prescribed amitriptyline (AMI) for hyperactivity and impulsivity. Data was systematically extracted from 50 outpatient clinic charts, including AMI treatment duration, dose, trough levels and adverse events. Mean age was 9.4 years (4.6–17.9); 40 were males and 10 females. 30 % had failed atomoxetine and 40 % had failed ≥3 ADHD medications. Mean dose was 1.3 ± 0.6 mg/kg/day, mean trough level 114.1 ± 50.5 ng/ml, mean duration 3.4 years. Clinical Global Impressions Scale-Improvement (CGI-I) was ≤2 in 60 % of patients at the final visit, and in 82 % of patients for at least 50 % of follow-ups. Cautious use of low dose AMI shows promise for treatment-resistant youth with ASD accompanied by hyperactivity, impulsivity, aggression and self injury.
doi_str_mv 10.1007/s10803-012-1647-0
format article
fullrecord <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_1373486638</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A333610098</galeid><ericid>EJ1000572</ericid><sourcerecordid>A333610098</sourcerecordid><originalsourceid>FETCH-LOGICAL-c629t-2a3f6b97360a02d8ac611e3c1ed7c47ed237760ceb61f71ead9db31ad19e8aa53</originalsourceid><addsrcrecordid>eNqN0t-L1DAQB_Aiiree_gE-KAUR9KFnJtMm7eNynnpyKNzqg08hm07XHP2xJqm6_72pu965ssJRaKHzmTSZfpPkMbATYEy-8sBKhhkDnoHIZcbuJDMoJGaYI7-bzBgIniEv5FHywPsrxlhVcn4_OeIIWCDIWfJhnl5ScINfkwn2O6WLMNabdGjSeWeDs-uwaW1Pqe3TL8MYvqY_bLzNx2B9ly6mJjd26WvrB1eT8w-Te41uPT3aPY-Tz2_OPp2-yy4-vj0_nV9kRvAqZFxjI5aVRME043WpjQAgNEC1NLmkmqOUghlaCmgkkK6reomga6io1LrA4-TFdt21G76N5IPqrDfUtrqnYfQKUGJeCoHlLWjBeVmizG9BuZBxntVEn_1Dr4bR9fHMvxWCAAk3aqVbUrZvhuC0mRZVc0QUMP2RqLIDakU9Od0OPTU2vt7zJwd8vGrqrDnY8HKvIZpAP8NKj96r88XlvoWtNTEU3lGj1s522m0UMDWlTm1Tp2Lq1JQ6xWLP090wxmVH9XXHn5hF8HwHtDe6bZzujfU3ThaCs7yK7snWkbPmunz2Pn6XFZLHOt_Wfaz1K3J_Tf2_u_sF1HnzTw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1326316171</pqid></control><display><type>article</type><title>A Retrospective Study of Amitriptyline in Youth with Autism Spectrum Disorders</title><source>Applied Social Sciences Index &amp; Abstracts (ASSIA)</source><source>Social Science Premium Collection</source><source>Springer Nature</source><source>Sociology Collection</source><source>ERIC</source><source>Education Collection</source><creator>Bhatti, Irfan ; Thome, Andrew ; Smith, Patricia Oxler ; Cook-Wiens, Galen ; Yeh, Hung Wen ; Gaffney, Gary R. ; Hellings, Jessica A.</creator><creatorcontrib>Bhatti, Irfan ; Thome, Andrew ; Smith, Patricia Oxler ; Cook-Wiens, Galen ; Yeh, Hung Wen ; Gaffney, Gary R. ; Hellings, Jessica A.</creatorcontrib><description>We performed a retrospective chart review of 50 youths with Autism Spectrum Disorder (ASD), prescribed amitriptyline (AMI) for hyperactivity and impulsivity. Data was systematically extracted from 50 outpatient clinic charts, including AMI treatment duration, dose, trough levels and adverse events. Mean age was 9.4 years (4.6–17.9); 40 were males and 10 females. 30 % had failed atomoxetine and 40 % had failed ≥3 ADHD medications. Mean dose was 1.3 ± 0.6 mg/kg/day, mean trough level 114.1 ± 50.5 ng/ml, mean duration 3.4 years. Clinical Global Impressions Scale-Improvement (CGI-I) was ≤2 in 60 % of patients at the final visit, and in 82 % of patients for at least 50 % of follow-ups. Cautious use of low dose AMI shows promise for treatment-resistant youth with ASD accompanied by hyperactivity, impulsivity, aggression and self injury.</description><identifier>ISSN: 0162-3257</identifier><identifier>EISSN: 1573-3432</identifier><identifier>DOI: 10.1007/s10803-012-1647-0</identifier><identifier>PMID: 23135317</identifier><identifier>CODEN: JADDDQ</identifier><language>eng</language><publisher>Boston: Springer US</publisher><subject>Adolescent ; Adolescents ; Adrenergic Uptake Inhibitors - therapeutic use ; Aggression ; Amitriptylene ; Amitriptyline ; Amitriptyline - therapeutic use ; Anxiety Disorders ; Atomoxetine Hydrochloride ; Autism ; Autism Spectrum Disorders ; Autistic spectrum disorders ; Behavior Problems ; Behavioral Science and Psychology ; Biological and medical sciences ; Child ; Child and School Psychology ; Child clinical studies ; Child Development Disorders, Pervasive - drug therapy ; Child, Preschool ; Complications and side effects ; Developmental disorders ; Dosage ; Dosage and administration ; Drug Therapy ; Female ; Humans ; Hyperactivity ; Impulsivity ; Infantile autism ; Male ; Medical sciences ; Neuropharmacology ; Neurosciences ; Original Paper ; Outcomes of Treatment ; Pediatrics ; Pervasive Developmental Disorders ; Pharmacology. Drug treatments ; Prognosis ; Propylamines - therapeutic use ; Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer ; Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease) ; Psychology ; Psychology. Psychoanalysis. Psychiatry ; Psychopathology. Psychiatry ; Psychopharmacology ; Public Health ; Retreatment ; Retrospective Studies ; Symptoms (Individual Disorders) ; Treatment Outcome ; Young people ; Youth</subject><ispartof>Journal of autism and developmental disorders, 2013-05, Vol.43 (5), p.1017-1027</ispartof><rights>Springer Science+Business Media, LLC 2012</rights><rights>2015 INIST-CNRS</rights><rights>COPYRIGHT 2013 Springer</rights><rights>Springer Science+Business Media New York 2013</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c629t-2a3f6b97360a02d8ac611e3c1ed7c47ed237760ceb61f71ead9db31ad19e8aa53</citedby><cites>FETCH-LOGICAL-c629t-2a3f6b97360a02d8ac611e3c1ed7c47ed237760ceb61f71ead9db31ad19e8aa53</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/1326316171/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$H</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/1326316171?pq-origsite=primo$$EHTML$$P50$$Gproquest$$H</linktohtml><link.rule.ids>314,776,780,12826,21358,21374,21375,27903,27904,30978,30979,33590,33591,33856,33857,34509,34510,43712,43859,44094,73968,74144,74386</link.rule.ids><backlink>$$Uhttp://eric.ed.gov/ERICWebPortal/detail?accno=EJ1000572$$DView record in ERIC$$Hfree_for_read</backlink><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=27562049$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23135317$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Bhatti, Irfan</creatorcontrib><creatorcontrib>Thome, Andrew</creatorcontrib><creatorcontrib>Smith, Patricia Oxler</creatorcontrib><creatorcontrib>Cook-Wiens, Galen</creatorcontrib><creatorcontrib>Yeh, Hung Wen</creatorcontrib><creatorcontrib>Gaffney, Gary R.</creatorcontrib><creatorcontrib>Hellings, Jessica A.</creatorcontrib><title>A Retrospective Study of Amitriptyline in Youth with Autism Spectrum Disorders</title><title>Journal of autism and developmental disorders</title><addtitle>J Autism Dev Disord</addtitle><addtitle>J Autism Dev Disord</addtitle><description>We performed a retrospective chart review of 50 youths with Autism Spectrum Disorder (ASD), prescribed amitriptyline (AMI) for hyperactivity and impulsivity. Data was systematically extracted from 50 outpatient clinic charts, including AMI treatment duration, dose, trough levels and adverse events. Mean age was 9.4 years (4.6–17.9); 40 were males and 10 females. 30 % had failed atomoxetine and 40 % had failed ≥3 ADHD medications. Mean dose was 1.3 ± 0.6 mg/kg/day, mean trough level 114.1 ± 50.5 ng/ml, mean duration 3.4 years. Clinical Global Impressions Scale-Improvement (CGI-I) was ≤2 in 60 % of patients at the final visit, and in 82 % of patients for at least 50 % of follow-ups. Cautious use of low dose AMI shows promise for treatment-resistant youth with ASD accompanied by hyperactivity, impulsivity, aggression and self injury.</description><subject>Adolescent</subject><subject>Adolescents</subject><subject>Adrenergic Uptake Inhibitors - therapeutic use</subject><subject>Aggression</subject><subject>Amitriptylene</subject><subject>Amitriptyline</subject><subject>Amitriptyline - therapeutic use</subject><subject>Anxiety Disorders</subject><subject>Atomoxetine Hydrochloride</subject><subject>Autism</subject><subject>Autism Spectrum Disorders</subject><subject>Autistic spectrum disorders</subject><subject>Behavior Problems</subject><subject>Behavioral Science and Psychology</subject><subject>Biological and medical sciences</subject><subject>Child</subject><subject>Child and School Psychology</subject><subject>Child clinical studies</subject><subject>Child Development Disorders, Pervasive - drug therapy</subject><subject>Child, Preschool</subject><subject>Complications and side effects</subject><subject>Developmental disorders</subject><subject>Dosage</subject><subject>Dosage and administration</subject><subject>Drug Therapy</subject><subject>Female</subject><subject>Humans</subject><subject>Hyperactivity</subject><subject>Impulsivity</subject><subject>Infantile autism</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Neuropharmacology</subject><subject>Neurosciences</subject><subject>Original Paper</subject><subject>Outcomes of Treatment</subject><subject>Pediatrics</subject><subject>Pervasive Developmental Disorders</subject><subject>Pharmacology. Drug treatments</subject><subject>Prognosis</subject><subject>Propylamines - therapeutic use</subject><subject>Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer</subject><subject>Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease)</subject><subject>Psychology</subject><subject>Psychology. Psychoanalysis. Psychiatry</subject><subject>Psychopathology. Psychiatry</subject><subject>Psychopharmacology</subject><subject>Public Health</subject><subject>Retreatment</subject><subject>Retrospective Studies</subject><subject>Symptoms (Individual Disorders)</subject><subject>Treatment Outcome</subject><subject>Young people</subject><subject>Youth</subject><issn>0162-3257</issn><issn>1573-3432</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>7SW</sourceid><sourceid>7QJ</sourceid><sourceid>ALSLI</sourceid><sourceid>CJNVE</sourceid><sourceid>HEHIP</sourceid><sourceid>M0P</sourceid><sourceid>M2R</sourceid><sourceid>M2S</sourceid><recordid>eNqN0t-L1DAQB_Aiiree_gE-KAUR9KFnJtMm7eNynnpyKNzqg08hm07XHP2xJqm6_72pu965ssJRaKHzmTSZfpPkMbATYEy-8sBKhhkDnoHIZcbuJDMoJGaYI7-bzBgIniEv5FHywPsrxlhVcn4_OeIIWCDIWfJhnl5ScINfkwn2O6WLMNabdGjSeWeDs-uwaW1Pqe3TL8MYvqY_bLzNx2B9ly6mJjd26WvrB1eT8w-Te41uPT3aPY-Tz2_OPp2-yy4-vj0_nV9kRvAqZFxjI5aVRME043WpjQAgNEC1NLmkmqOUghlaCmgkkK6reomga6io1LrA4-TFdt21G76N5IPqrDfUtrqnYfQKUGJeCoHlLWjBeVmizG9BuZBxntVEn_1Dr4bR9fHMvxWCAAk3aqVbUrZvhuC0mRZVc0QUMP2RqLIDakU9Od0OPTU2vt7zJwd8vGrqrDnY8HKvIZpAP8NKj96r88XlvoWtNTEU3lGj1s522m0UMDWlTm1Tp2Lq1JQ6xWLP090wxmVH9XXHn5hF8HwHtDe6bZzujfU3ThaCs7yK7snWkbPmunz2Pn6XFZLHOt_Wfaz1K3J_Tf2_u_sF1HnzTw</recordid><startdate>20130501</startdate><enddate>20130501</enddate><creator>Bhatti, Irfan</creator><creator>Thome, Andrew</creator><creator>Smith, Patricia Oxler</creator><creator>Cook-Wiens, Galen</creator><creator>Yeh, Hung Wen</creator><creator>Gaffney, Gary R.</creator><creator>Hellings, Jessica A.</creator><general>Springer US</general><general>Springer</general><general>Springer Nature B.V</general><scope>7SW</scope><scope>BJH</scope><scope>BNH</scope><scope>BNI</scope><scope>BNJ</scope><scope>BNO</scope><scope>ERI</scope><scope>PET</scope><scope>REK</scope><scope>WWN</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>ISR</scope><scope>0-V</scope><scope>3V.</scope><scope>7QJ</scope><scope>7RV</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88B</scope><scope>88E</scope><scope>88G</scope><scope>88J</scope><scope>8A4</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>ALSLI</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>CJNVE</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>HEHIP</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>M0P</scope><scope>M0R</scope><scope>M0S</scope><scope>M1P</scope><scope>M2M</scope><scope>M2O</scope><scope>M2R</scope><scope>M2S</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEDU</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PSYQQ</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>20130501</creationdate><title>A Retrospective Study of Amitriptyline in Youth with Autism Spectrum Disorders</title><author>Bhatti, Irfan ; Thome, Andrew ; Smith, Patricia Oxler ; Cook-Wiens, Galen ; Yeh, Hung Wen ; Gaffney, Gary R. ; Hellings, Jessica A.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c629t-2a3f6b97360a02d8ac611e3c1ed7c47ed237760ceb61f71ead9db31ad19e8aa53</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Adolescent</topic><topic>Adolescents</topic><topic>Adrenergic Uptake Inhibitors - therapeutic use</topic><topic>Aggression</topic><topic>Amitriptylene</topic><topic>Amitriptyline</topic><topic>Amitriptyline - therapeutic use</topic><topic>Anxiety Disorders</topic><topic>Atomoxetine Hydrochloride</topic><topic>Autism</topic><topic>Autism Spectrum Disorders</topic><topic>Autistic spectrum disorders</topic><topic>Behavior Problems</topic><topic>Behavioral Science and Psychology</topic><topic>Biological and medical sciences</topic><topic>Child</topic><topic>Child and School Psychology</topic><topic>Child clinical studies</topic><topic>Child Development Disorders, Pervasive - drug therapy</topic><topic>Child, Preschool</topic><topic>Complications and side effects</topic><topic>Developmental disorders</topic><topic>Dosage</topic><topic>Dosage and administration</topic><topic>Drug Therapy</topic><topic>Female</topic><topic>Humans</topic><topic>Hyperactivity</topic><topic>Impulsivity</topic><topic>Infantile autism</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Neuropharmacology</topic><topic>Neurosciences</topic><topic>Original Paper</topic><topic>Outcomes of Treatment</topic><topic>Pediatrics</topic><topic>Pervasive Developmental Disorders</topic><topic>Pharmacology. Drug treatments</topic><topic>Prognosis</topic><topic>Propylamines - therapeutic use</topic><topic>Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer</topic><topic>Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease)</topic><topic>Psychology</topic><topic>Psychology. Psychoanalysis. Psychiatry</topic><topic>Psychopathology. Psychiatry</topic><topic>Psychopharmacology</topic><topic>Public Health</topic><topic>Retreatment</topic><topic>Retrospective Studies</topic><topic>Symptoms (Individual Disorders)</topic><topic>Treatment Outcome</topic><topic>Young people</topic><topic>Youth</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Bhatti, Irfan</creatorcontrib><creatorcontrib>Thome, Andrew</creatorcontrib><creatorcontrib>Smith, Patricia Oxler</creatorcontrib><creatorcontrib>Cook-Wiens, Galen</creatorcontrib><creatorcontrib>Yeh, Hung Wen</creatorcontrib><creatorcontrib>Gaffney, Gary R.</creatorcontrib><creatorcontrib>Hellings, Jessica A.</creatorcontrib><collection>ERIC</collection><collection>ERIC (Ovid)</collection><collection>ERIC</collection><collection>ERIC</collection><collection>ERIC (Legacy Platform)</collection><collection>ERIC( SilverPlatter )</collection><collection>ERIC</collection><collection>ERIC PlusText (Legacy Platform)</collection><collection>Education Resources Information Center (ERIC)</collection><collection>ERIC</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Science in Context</collection><collection>ProQuest Social Sciences Premium Collection</collection><collection>ProQuest Central (Corporate)</collection><collection>Applied Social Sciences Index &amp; Abstracts (ASSIA)</collection><collection>ProQuest Nursing and Allied Health Journals</collection><collection>Neurosciences Abstracts</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Education Database (Alumni Edition)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Psychology Database (Alumni)</collection><collection>Social Science Database (Alumni Edition)</collection><collection>Education Periodicals</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>Social Science Premium Collection</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Education Collection</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>Sociology Collection</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>Education Database (ProQuest)</collection><collection>Consumer Health Database</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Psychology Database (ProQuest)</collection><collection>Research Library</collection><collection>Social Science Database</collection><collection>Sociology Database (ProQuest)</collection><collection>Research Library (Corporate)</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>ProQuest One Education</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of autism and developmental disorders</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Bhatti, Irfan</au><au>Thome, Andrew</au><au>Smith, Patricia Oxler</au><au>Cook-Wiens, Galen</au><au>Yeh, Hung Wen</au><au>Gaffney, Gary R.</au><au>Hellings, Jessica A.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><ericid>EJ1000572</ericid><atitle>A Retrospective Study of Amitriptyline in Youth with Autism Spectrum Disorders</atitle><jtitle>Journal of autism and developmental disorders</jtitle><stitle>J Autism Dev Disord</stitle><addtitle>J Autism Dev Disord</addtitle><date>2013-05-01</date><risdate>2013</risdate><volume>43</volume><issue>5</issue><spage>1017</spage><epage>1027</epage><pages>1017-1027</pages><issn>0162-3257</issn><eissn>1573-3432</eissn><coden>JADDDQ</coden><abstract>We performed a retrospective chart review of 50 youths with Autism Spectrum Disorder (ASD), prescribed amitriptyline (AMI) for hyperactivity and impulsivity. Data was systematically extracted from 50 outpatient clinic charts, including AMI treatment duration, dose, trough levels and adverse events. Mean age was 9.4 years (4.6–17.9); 40 were males and 10 females. 30 % had failed atomoxetine and 40 % had failed ≥3 ADHD medications. Mean dose was 1.3 ± 0.6 mg/kg/day, mean trough level 114.1 ± 50.5 ng/ml, mean duration 3.4 years. Clinical Global Impressions Scale-Improvement (CGI-I) was ≤2 in 60 % of patients at the final visit, and in 82 % of patients for at least 50 % of follow-ups. Cautious use of low dose AMI shows promise for treatment-resistant youth with ASD accompanied by hyperactivity, impulsivity, aggression and self injury.</abstract><cop>Boston</cop><pub>Springer US</pub><pmid>23135317</pmid><doi>10.1007/s10803-012-1647-0</doi><tpages>11</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0162-3257
ispartof Journal of autism and developmental disorders, 2013-05, Vol.43 (5), p.1017-1027
issn 0162-3257
1573-3432
language eng
recordid cdi_proquest_miscellaneous_1373486638
source Applied Social Sciences Index & Abstracts (ASSIA); Social Science Premium Collection; Springer Nature; Sociology Collection; ERIC; Education Collection
subjects Adolescent
Adolescents
Adrenergic Uptake Inhibitors - therapeutic use
Aggression
Amitriptylene
Amitriptyline
Amitriptyline - therapeutic use
Anxiety Disorders
Atomoxetine Hydrochloride
Autism
Autism Spectrum Disorders
Autistic spectrum disorders
Behavior Problems
Behavioral Science and Psychology
Biological and medical sciences
Child
Child and School Psychology
Child clinical studies
Child Development Disorders, Pervasive - drug therapy
Child, Preschool
Complications and side effects
Developmental disorders
Dosage
Dosage and administration
Drug Therapy
Female
Humans
Hyperactivity
Impulsivity
Infantile autism
Male
Medical sciences
Neuropharmacology
Neurosciences
Original Paper
Outcomes of Treatment
Pediatrics
Pervasive Developmental Disorders
Pharmacology. Drug treatments
Prognosis
Propylamines - therapeutic use
Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer
Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease)
Psychology
Psychology. Psychoanalysis. Psychiatry
Psychopathology. Psychiatry
Psychopharmacology
Public Health
Retreatment
Retrospective Studies
Symptoms (Individual Disorders)
Treatment Outcome
Young people
Youth
title A Retrospective Study of Amitriptyline in Youth with Autism Spectrum Disorders
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-21T15%3A56%3A37IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20Retrospective%20Study%20of%20Amitriptyline%20in%20Youth%20with%20Autism%20Spectrum%20Disorders&rft.jtitle=Journal%20of%20autism%20and%20developmental%20disorders&rft.au=Bhatti,%20Irfan&rft.date=2013-05-01&rft.volume=43&rft.issue=5&rft.spage=1017&rft.epage=1027&rft.pages=1017-1027&rft.issn=0162-3257&rft.eissn=1573-3432&rft.coden=JADDDQ&rft_id=info:doi/10.1007/s10803-012-1647-0&rft_dat=%3Cgale_proqu%3EA333610098%3C/gale_proqu%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c629t-2a3f6b97360a02d8ac611e3c1ed7c47ed237760ceb61f71ead9db31ad19e8aa53%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1326316171&rft_id=info:pmid/23135317&rft_galeid=A333610098&rft_ericid=EJ1000572&rfr_iscdi=true